Patrizia Porazzi
Overview
Explore the profile of Patrizia Porazzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al.
Cancer Cell
. 2025 Feb;
43(3):537-551.e7.
PMID: 39983725
Tumor resistance to chimeric antigen receptor T cell (CAR-T) and, in general, to adoptive cell immunotherapies (ACTs) is a major challenge in the clinic. We hypothesized that inhibiting the tumor...
2.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al.
Cancer Cell
. 2024 Dec;
43(1):49-68.e9.
PMID: 39642889
T cell-based immunotherapies have demonstrated effectiveness in treating diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) but predicting response and understanding resistance remains a challenge. To address this,...
3.
Patel R, Ghilardi G, Zhang Y, Chiang Y, Xie W, Guruprasad P, et al.
Sci Immunol
. 2024 Jul;
9(97):eadn6509.
PMID: 39028827
Most patients treated with US Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid...
4.
Guruprasad P, Carturan A, Zhang Y, Cho J, Kumashie K, Patel R, et al.
Nat Immunol
. 2024 Jun;
25(6):1020-1032.
PMID: 38831106
The efficacy of T cell-based immunotherapies is limited by immunosuppressive pressures in the tumor microenvironment. Here we show a predominant role for the interaction between BTLA on effector T cells...
5.
Ghilardi G, Paruzzo L, Svoboda J, Chong E, Shestov A, Chen L, et al.
Blood Adv
. 2023 Dec;
8(3):653-666.
PMID: 38113468
Lymphodepletion (LD) is an integral component of chimeric antigen receptor T-cell (CART) immunotherapies. In this study, we compared the safety and efficacy of bendamustine (Benda) to standard fludarabine/cyclophosphamide (Flu/Cy) LD...
6.
Zhang Y, Patel R, Kim K, Cho H, Jo J, Jeong S, et al.
Mol Cancer
. 2023 Dec;
22(1):200.
PMID: 38066564
Background: Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contribute to this failure, including CD19-negative...
7.
Ruella M, Korell F, Porazzi P, Maus M
Nat Rev Drug Discov
. 2023 Nov;
22(12):976-995.
PMID: 37907724
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic approach for the treatment of patients with chemotherapy-refractory or relapsed blood cancers, including acute lymphoblastic leukaemia, diffuse large...
8.
Wilde L, Porazzi P, Trotta R, De Dominici M, Palmisiano N, Keiffer G, et al.
Leuk Res
. 2023 Apr;
129:107075.
PMID: 37079999
Purpose: Despite advances in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), outcomes for relapsed/refractory (R/R) disease remain poor. Preclinical studies suggest that the combination of the CDK4/6 inhibitor palbociclib...
9.
Lee Y, Yang N, Chun I, Porazzi P, Carturan A, Paruzzo L, et al.
J Immunother Cancer
. 2023 Apr;
11(4).
PMID: 37055217
Immunotherapy has revolutionized the treatment of cancer. In particular, immune checkpoint blockade, bispecific antibodies, and adoptive T-cell transfer have yielded unprecedented clinical results in hematological malignancies and solid cancers. While...
10.
Isabelle C, Johnson W, McConnell K, Vogel A, Brammer J, Boles A, et al.
Blood Adv
. 2023 Mar;
7(14):3637-3641.
PMID: 36989058
No abstract available.